164 related articles for article (PubMed ID: 30542513)
1. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.
Ueda S; Miyahara Y; Nagata Y; Sato E; Shiraishi T; Harada N; Ikeda H; Shiku H; Kageyama S
Oncotarget; 2018 Nov; 9(89):35997-36011. PubMed ID: 30542513
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
3. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R
J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776
[TBL] [Abstract][Full Text] [Related]
4. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
[TBL] [Abstract][Full Text] [Related]
5. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
[TBL] [Abstract][Full Text] [Related]
6. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Nagata Y; Kageyama S; Ishikawa T; Kokura S; Okayama T; Abe T; Murakami M; Otsuka K; Ariyoshi T; Kojima T; Taniguchi K; Kobayashi S; Shimada H; Yajima S; Suzuki T; Hirano S; Tsuchikawa T; Shichinohe T; Ueda S; Kanetaka K; Yoneda A; Wada H; Doki Y; Yamaue H; Katsuda M; Ohi M; Yasuda H; Kondo K; Kataoka M; Kodera Y; Koike M; Shiraishi T; Miyahara Y; Goshima N; Fukuda E; Yamaguchi K; Sato E; Ikeda H; Yamada T; Osako M; Hirai K; Miyamoto H; Watanabe T; Shiku H
Cancer Immunol Immunother; 2022 Nov; 71(11):2743-2755. PubMed ID: 35429246
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression.
Hou Z; Liang X; Wang X; Zhou Z; Shi G
Oncol Lett; 2020 Jun; 19(6):3982-3992. PubMed ID: 32382343
[TBL] [Abstract][Full Text] [Related]
9. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
Kakimoto T; Matsumine A; Kageyama S; Asanuma K; Matsubara T; Nakamura T; Iino T; Ikeda H; Shiku H; Sudo A
Oncol Lett; 2019 Apr; 17(4):3937-3943. PubMed ID: 30881511
[TBL] [Abstract][Full Text] [Related]
11. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
12. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H; Shiku H
BMC Cancer; 2020 Jun; 20(1):606. PubMed ID: 32600281
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.
Hashimoto K; Nishimura S; Ito T; Oka N; Kakinoki R; Akagi M
Eur J Histochem; 2022 Jun; 66(3):. PubMed ID: 35736245
[TBL] [Abstract][Full Text] [Related]
15. Limited expression of cancer-testis antigens in renal cell carcinoma patients.
Soga N; Hori Y; Yamakado K; Ikeda H; Imai N; Kageyama S; Nakase K; Yuta A; Hayashi N; Shiku H; Sugimura Y
Mol Clin Oncol; 2013 Mar; 1(2):326-330. PubMed ID: 24649170
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
17. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
Saito T; Wada H; Yamasaki M; Miyata H; Nishikawa H; Sato E; Kageyama S; Shiku H; Mori M; Doki Y
Vaccine; 2014 Oct; 32(45):5901-7. PubMed ID: 25218300
[TBL] [Abstract][Full Text] [Related]
18. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
19. Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M
Medicine (Baltimore); 2023 Jun; 102(22):e33908. PubMed ID: 37266606
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck.
Veit JA; Heine D; Thierauf J; Lennerz J; Shetty S; Schuler PJ; Whiteside T; Beutner D; Meyer M; Grünewald I; Ritter G; Gnjatic S; Sikora AG; Hoffmann TK; Laban S
Head Neck; 2016 Jul; 38(7):1008-16. PubMed ID: 26874246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]